Sergios Gatidis1,2, Holger Schmidt3, Christian la Fougère4, Konstantin Nikolaou3, Nina F Schwenzer3, Jürgen F Schäfer3. 1. Department of Radiology, Diagnostic and Interventional Radiology, University of Tübingen, Tübingen, Germany. sergios.gatidis@med.uni-tuebingen.de. 2. , Hoppe-Seyler-Str. 3, 72076, Tübingen, Germany. sergios.gatidis@med.uni-tuebingen.de. 3. Department of Radiology, Diagnostic and Interventional Radiology, University of Tübingen, Tübingen, Germany. 4. Department of Radiology, Nuclear Medicine, University of Tübingen, Tübingen, Germany.
Abstract
PURPOSE: To explore the feasibility of reducing administered tracer activities and to assess optimal activities for combined 18F-FDG-PET/MRI in pediatric oncology. METHODS: 30 18F-FDG-PET/MRI examinations were performed on 24 patients with known or suspected solid tumors (10 girls, 14 boys, age 12 ± 5.6 [1-18] years; PET scan duration: 4 min per bed position). Low-activity PET images were retrospectively simulated from the originally acquired data sets using randomized undersampling of list mode data. PET data of different simulated administered activities (0.25-2.5 MBq/kg body weight) were reconstructed with or without point spread function (PSF) modeling. Mean and maximum standardized uptake values (SUVmean and SUVmax) as well as SUV variation (SUVvar) were measured in physiologic organs and focal FDG-avid lesions. Detectability of organ structures and of focal 18F-FDG-avid lesions as well as the occurrence of false-positive PET lesions were assessed at different simulated tracer activities. RESULTS: Subjective image quality steadily declined with decreasing tracer activities. Compared to the originally acquired data sets, mean relative deviations of SUVmean and SUVmax were below 5 % at 18F-FDG activities of 1.5 MBq/kg or higher. Over 95 % of anatomic structures and all pathologic focal lesions were detectable at 1.5 MBq/kg 18F-FDG. Detectability of anatomic structures and focal lesions was significantly improved using PSF. No false-positive focal lesions were observed at tracer activities of 1 MBq/kg 18F-FDG or higher. Administration of 18F-FDG activities of 1.5 MBq/kg is, thus, feasible without obvious diagnostic shortcomings, which is equivalent to a dose reduction of more than 50 % compared to current recommendations. CONCLUSION: Significant reduction in administered 18F-FDG tracer activities is feasible in pediatric oncologic PET/MRI. Appropriate activities of 18F-FDG or other tracers for specific clinical questions have to be further established in selected patient populations.
PURPOSE: To explore the feasibility of reducing administered tracer activities and to assess optimal activities for combined 18F-FDG-PET/MRI in pediatric oncology. METHODS: 30 18F-FDG-PET/MRI examinations were performed on 24 patients with known or suspected solid tumors (10 girls, 14 boys, age 12 ± 5.6 [1-18] years; PET scan duration: 4 min per bed position). Low-activity PET images were retrospectively simulated from the originally acquired data sets using randomized undersampling of list mode data. PET data of different simulated administered activities (0.25-2.5 MBq/kg body weight) were reconstructed with or without point spread function (PSF) modeling. Mean and maximum standardized uptake values (SUVmean and SUVmax) as well as SUV variation (SUVvar) were measured in physiologic organs and focal FDG-avid lesions. Detectability of organ structures and of focal 18F-FDG-avid lesions as well as the occurrence of false-positive PET lesions were assessed at different simulated tracer activities. RESULTS: Subjective image quality steadily declined with decreasing tracer activities. Compared to the originally acquired data sets, mean relative deviations of SUVmean and SUVmax were below 5 % at 18F-FDG activities of 1.5 MBq/kg or higher. Over 95 % of anatomic structures and all pathologic focal lesions were detectable at 1.5 MBq/kg 18F-FDG. Detectability of anatomic structures and focal lesions was significantly improved using PSF. No false-positive focal lesions were observed at tracer activities of 1 MBq/kg 18F-FDG or higher. Administration of 18F-FDG activities of 1.5 MBq/kg is, thus, feasible without obvious diagnostic shortcomings, which is equivalent to a dose reduction of more than 50 % compared to current recommendations. CONCLUSION: Significant reduction in administered 18F-FDG tracer activities is feasible in pediatric oncologic PET/MRI. Appropriate activities of 18F-FDG or other tracers for specific clinical questions have to be further established in selected patient populations.
Authors: Mark Oehmigen; Susanne Ziegler; Bjoern W Jakoby; Jens-Christoph Georgi; Daniel H Paulus; Harald H Quick Journal: J Nucl Med Date: 2014-07-08 Impact factor: 10.057
Authors: Sergios Gatidis; Christian Würslin; Ferdinand Seith; Jürgen F Schäfer; Christian la Fougère; Konstantin Nikolaou; Nina F Schwenzer; Holger Schmidt Journal: Hell J Nucl Med Date: 2016-03-01 Impact factor: 1.102
Authors: Adam M Alessio; Marla Sammer; Grace S Phillips; Vivek Manchanda; Brandt C Mohr; Marguerite T Parisi Journal: J Nucl Med Date: 2011-06-16 Impact factor: 10.057
Authors: Frederic H Fahey; Henry Hee-Seong Bom; Arturo Chiti; Yun Young Choi; Gang Huang; Michael Lassmann; Norman Laurin; Fernando Mut; Rodolfo Nuñez-Miller; Darin O'Keeffe; Prasanta Pradhan; Andrew M Scott; Shaoli Song; Nischal Soni; Mayuki Uchiyama; Luis Vargas Journal: J Nucl Med Date: 2015-03-12 Impact factor: 10.057
Authors: J Stauss; C Franzius; T Pfluger; K U Juergens; L Biassoni; J Begent; R Kluge; H Amthauer; T Voelker; L Højgaard; S Barrington; S Hain; T Lynch; K Hahn Journal: Eur J Nucl Med Mol Imaging Date: 2008-08 Impact factor: 9.236
Authors: Sergios Gatidis; Holger Schmidt; Brigitte Gücke; Ilja Bezrukov; Guido Seitz; Martin Ebinger; Matthias Reimold; Christina A Pfannenberg; Konstantin Nikolaou; Nina F Schwenzer; Jürgen F Schäfer Journal: Invest Radiol Date: 2016-01 Impact factor: 6.016
Authors: Jürgen F Schäfer; Sergios Gatidis; Holger Schmidt; Brigitte Gückel; Ilja Bezrukov; Christina A Pfannenberg; Matthias Reimold; Martin Ebinger; Jörg Fuchs; Claus D Claussen; Nina F Schwenzer Journal: Radiology Date: 2014-05-31 Impact factor: 11.105
Authors: Christina P W Cox; Daniëlle M E van Assema; Frederik A Verburg; Tessa Brabander; Mark Konijnenberg; Marcel Segbers Journal: EJNMMI Res Date: 2021-07-19 Impact factor: 3.138
Authors: Jeffrey P Schmall; Suleman Surti; Hansel J Otero; Sabah Servaes; Joel S Karp; Lisa J States Journal: J Nucl Med Date: 2020-06-01 Impact factor: 11.082
Authors: Roelof van Ewijk; Reineke A Schoot; Monika Sparber-Sauer; Simone A J Ter Horst; Nina Jehanno; Lise Borgwardt; Bart de Keizer; Johannes H M Merks; Alberto de Luca; Kieran McHugh; Thekla von Kalle; Jürgen F Schäfer; Rick R van Rijn Journal: Pediatr Radiol Date: 2021-06-17